- Home
- CAC vs MLYS Comparison
CAC vs MLYS Comparison
Compare CAC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAC
- MLYS
- Stock Information
- Founded
- CAC 1875
- MLYS 2019
- Country
- CAC United States
- MLYS United States
- Employees
- CAC N/A
- MLYS N/A
- Industry
- CAC Major Banks
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- CAC Finance
- MLYS Health Care
- Exchange
- CAC Nasdaq
- MLYS Nasdaq
- Market Cap
- CAC 688.3M
- MLYS 890.6M
- IPO Year
- CAC 1997
- MLYS 2023
- Fundamental
- Price
- CAC $41.23
- MLYS $39.94
- Analyst Decision
- CAC Buy
- MLYS Strong Buy
- Analyst Count
- CAC 3
- MLYS 6
- Target Price
- CAC $48.00
- MLYS $42.60
- AVG Volume (30 Days)
- CAC 56.5K
- MLYS 2.6M
- Earning Date
- CAC 10-28-2025
- MLYS 11-10-2025
- Dividend Yield
- CAC 4.22%
- MLYS N/A
- EPS Growth
- CAC 4.80
- MLYS N/A
- EPS
- CAC 3.11
- MLYS N/A
- Revenue
- CAC $197,501,000.00
- MLYS N/A
- Revenue This Year
- CAC $42.11
- MLYS N/A
- Revenue Next Year
- CAC $5.51
- MLYS N/A
- P/E Ratio
- CAC $12.78
- MLYS N/A
- Revenue Growth
- CAC 21.74
- MLYS N/A
- 52 Week Low
- CAC $34.53
- MLYS $8.24
- 52 Week High
- CAC $50.07
- MLYS $39.20
- Technical
- Relative Strength Index (RSI)
- CAC 59.03
- MLYS 85.37
- Support Level
- CAC $39.50
- MLYS $34.59
- Resistance Level
- CAC $40.75
- MLYS $39.20
- Average True Range (ATR)
- CAC 0.88
- MLYS 3.04
- MACD
- CAC -0.01
- MLYS 0.63
- Stochastic Oscillator
- CAC 87.63
- MLYS 98.72
About CAC Camden National Corporation
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.